- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02970656
A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Intensive management of type 1 diabetes (T1D) among youth as recommended by the American Diabetes Association requires a complex set of self-management activities that create high levels of perceived stress in youth and families. In individuals exposed to chronic stress, such as that of a chronic condition, the body responds with physiological and hormonal responses to adapt. These responses can be harmful (e.g., higher glucose levels, higher HbA1c). Such harmful effects may be ameliorated by programs that reduce psychosocial stress.
The investigators have found an Internet-delivered coping skills training program combined with a diabetes education program significantly improved HbA1c and QOL for youth with T1D. Self-reported perceived stress mediated these outcomes. There has been little to no examination, however, of whether a reduction in self-reported perceived stress is associated with a reduction in biochemical markers of stress which could explain the positive impact on HbA1c. It is critically important to understand the physiologic as well as the psychosocial mechanisms associated with such interventions in order to improve glycemic control in youth with this chronic autoimmune condition. If such interventions affect biomarkers of stress, it would be important to strengthen the stress reduction activities embedded in such interventions, such as meditation, to further improve metabolic control. Thus, aims of this pilot/feasibility study are to:
- Determine the feasibility and reliability of collection of saliva for the measurement of three stress biomarkers at awakening and 30-45 minutes later over 3 days at home in 20 youth (age 11-14 years). These biomarkers include cortisol to assess hypothalamic-pituitary-adrenal axis functioning; alpha-amylase (s-AA) to assess the sympathetic-adrenal-medullary system, and salivary immunoglobulin A (s-IgA) to assess stress-related immune changes. This aim will allow the investigators to determine the feasibility of recruiting youth to provide such data in a larger trial by assessing the percent of youth who agree to participate and adhere to the salivary collection protocol, using actigraphy to document awakening time and Medication Event Monitoring System (MEMS) caps monitoring to determine time of salivary collection. Patterns and variability of stress biomarker levels over 3 days will be used to assess intra-individual variability and relationships with self-reported daily stressors and self-reported perceived stress.
- Conduct a pilot study of Teens.Connect, a combination of the investigators' previous TEENCOPE™ and Managing Diabetes programs with 40 youth to determine whether alterations in stress biomarkers are associated with self-reported perceived stress and HbA1c.
- Assess epigenetic components of these responses by examining the gene-environment interaction of the top 14 targeted candidate genes and epigenome wide effects of teens' stress biomarkers and their influence on HbA1c levels over time. Candidate genes will be measured at baseline and DNA methylation patterns will be measured at baseline and then again at 6 months follow-up using the Oragene saliva collection kits.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Connecticut
-
West Haven, Connecticut, Yhdysvallat, 06516-7399
- Yale School of Nursing
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- diagnosed with T1D for at least 6 months;
- age 11 to 14 years
- naïve to TEENCOPE and/or Managing Diabetes
- assent and parent/guardian consent to participate in the study
Exclusion Criteria:
- medical condition that impacts cortisol functioning
- takes medications that impact cortisol, except diabetes medications
- sleeps less than 6 hours per night
- smokes
- takes oral contraceptives
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Teens.Connect
The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes.
Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents.
TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior.
Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete.
Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner.
Youth interact with each other on an online discussion board moderated by a clinical psychologist.
|
Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
|
Ei väliintuloa: Control
Wait listing will serve as the control condition.
Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service.
Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Glycosylated Hemoglobin (HbA1c)
Aikaikkuna: baseline
|
Bayer Diagnostics DCA2000® (normal range = 4.2-6.3%)
|
baseline
|
Glycosylated Hemoglobin (HbA1c)
Aikaikkuna: 6 months
|
Bayer Diagnostics DCA2000® (normal range = 4.2-6.3%)
|
6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Perceived Stress Scale
Aikaikkuna: baseline
|
A 14-item scale that measures the degree to which situations in one's life are appraised as stressful.
Items assess feelings of stress, hassles, and coping during the past month.
Respondents rate items on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with higher scores indicative of greater perceived stress and less effective coping.
|
baseline
|
Perceived Stress Scale
Aikaikkuna: 6 months
|
A 14-item scale that measures the degree to which situations in one's life are appraised as stressful.
Items assess feelings of stress, hassles, and coping during the past month.
Respondents rate items on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with higher scores indicative of greater perceived stress and less effective coping.
|
6 months
|
Adolescent Stress Questionnaire (ASQ)
Aikaikkuna: baseline
|
A 94-item inventory of common adolescent stressors.
Each item (stressor) is rated on a 5-point Likert scale where 1=Not at all stressful (or is irrelevant to me); 2=A little stressful; 3=Moderately stressful; 4=Quite stressful; and 5=Very stressful.
|
baseline
|
Adolescent Stress Questionnaire (ASQ)
Aikaikkuna: 6 months
|
A 94-item inventory of common adolescent stressors.
Each item (stressor) is rated on a 5-point Likert scale where 1=Not at all stressful (or is irrelevant to me); 2=A little stressful; 3=Moderately stressful; 4=Quite stressful; and 5=Very stressful.
|
6 months
|
Responses to Stress Questionnaire for Diabetes (RSQ)
Aikaikkuna: baseline
|
A 69-item scale asking the participant to report frequency of diabetes related stressors (12 items) and their responses to those stressors (57 items).
Frequencies are reported on a 4-point scale ranging from 0 (never) to 3 (almost every day) for stressors, and 1 (not at all) to 4 (a lot) for stress responses.
|
baseline
|
Responses to Stress Questionnaire for Diabetes (RSQ)
Aikaikkuna: 6 months
|
A 69-item scale asking the participant to report frequency of diabetes related stressors (12 items) and their responses to those stressors (57 items).
Frequencies are reported on a 4-point scale ranging from 0 (never) to 3 (almost every day) for stressors, and 1 (not at all) to 4 (a lot) for stress responses.
|
6 months
|
Stress Biomarkers
Aikaikkuna: over 3 days at baseline
|
cortisol, alpha-amylase (s-AA), and salivary immunoglobulin A (s-IgA) determined by salivary collection at awakening and 30-45 minutes later over 3 days
|
over 3 days at baseline
|
Stress Biomarkers
Aikaikkuna: over 2 days at 6 months
|
cortisol, alpha-amylase (s-AA), and salivary immunoglobulin A (s-IgA) determined by salivary collection at awakening and 30-45 minutes later over 2 days
|
over 2 days at 6 months
|
Awakening and sleep time
Aikaikkuna: over 3 days at baseline
|
wrist-worn accelerometer
|
over 3 days at baseline
|
Awakening and sleep time
Aikaikkuna: over 2 days at 6 months
|
wrist-worn accelerometer
|
over 2 days at 6 months
|
Genotype & DNA Methylation
Aikaikkuna: baseline
|
Saliva collection
|
baseline
|
DNA Methylation
Aikaikkuna: 6 months
|
Saliva collection
|
6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Margaret Grey, DrPH, RN, Yale School of Nursing
- Päätutkija: Jacquelyn Taylor, PhD, PNP-BC, Yale School of Nursing
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 1503015414
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Diabetes mellitus, tyyppi 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.ValmisDiabetes mellitus, tyyppi 1 | Tyypin 1 diabetes | Diabetes tyyppi 1 | Tyypin 1 diabetes mellitus | Autoimmuuni Diabetes | Diabetes mellitus, insuliinista riippuvainen | Nuorten diabetes | Diabetes, Autoimmuuni | Insuliiniriippuvainen diabetes mellitus 1 | Diabetes mellitus, insuliinista riippuvainen, 1 | Diabetes... ja muut ehdotYhdysvallat
-
University of California, San FranciscoJuvenile Diabetes Research FoundationValmisTyypin 1 diabetes mellitus | Diabetes mellitus, tyyppi I | Insuliiniriippuvainen diabetes mellitus 1 | Diabetes mellitus, insuliinista riippuvainen, 1 | IDDMYhdysvallat, Australia
-
Capillary Biomedical, Inc.ValmisDiabetes mellitus, tyyppi 1 | Tyypin 1 diabetes | Tyypin 1 diabetes mellitus | Diabetes mellitus, insuliinista riippuvainen, 1Australia
-
Spiden AGDCB Research AGRekrytointiTyypin 1 diabetes mellitus | Tyypin 1 diabetes mellitus hypoglykemialla | Tyypin 1 diabetes mellitus ja hyperglykemiaSveitsi
-
Capillary Biomedical, Inc.LopetettuTyypin 1 diabetes | Tyypin 1 diabetes mellitus | Diabetes mellitus, tyyppi I | Diabetes mellitus, insuliinista riippuvainen, 1 | IDDMItävalta
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)ValmisTyypin 1 diabetes mellitus | T1DM | T1D | Uusi tyypin 1 diabetes mellitusYhdysvallat, Australia
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of...TuntematonTyypin 1 diabetes mellitus ja hyperglykemia | Tyypin 1 diabetes mellitus ja hypoglykemiaPuola
-
Ain Shams UniversityTuntematonTyypin 1 diabetes mellitus hypoglykemialla | tyypin 1 diabetesEgypti
-
SanofiValmisTyypin 1 diabetes - tyypin 2 diabetes mellitusUnkari, Venäjän federaatio, Saksa, Puola, Japani, Yhdysvallat, Suomi
-
University Hospital, CaenValmisTyypin 1 diabetes mellitus kypsyys alkaaRanska